NEULAND LABORATORIES LTD.

Neuland Laboratories Ltd has announced the closure of its trading window for dealing in the company's equity shares. This closure is in accordance with the company's Insider Trading Code and will be effective from July 1, 2026. The window will reopen 48 hours after the declaration of the financial results for the quarter ended June 30, 2026. The date for the Board Meeting to approve these financial results will be communicated separately.

Neuland Laboratories Ltd announced its FY26 financial results, reporting a total income of ₹2053.1 crore and EBITDA of ₹603.4 crore. The company corrected a typographical error in the press release header, changing "Q4FY26" to "FY26". The company's CEO, Saharsh Davuluri, expressed satisfaction with the strong finish to FY26 and highlighted the focus on execution, customer satisfaction, and investments in peptide manufacturing and a new R&D center.

Neuland Laboratories Ltd's board has recommended a final dividend of ₹34 (340%) per equity share with a face value of ₹10 each for the financial year 2025-26. The dividend will be paid on or after five days from the declaration at the AGM. The board also approved the audited financial results for the year ended March 31, 2026, and appointed Dr. Mauricio Futran as an Additional Director. Additionally, the company approved convening the 42nd AGM on August 4, 2026, and fixed the record date for the dividend as July 24, 2026. The company also plans to enhance capacity at Unit 1 with an investment of ₹143.4 crores.

Neuland Laboratories Ltd's board approved the audited financial results for the year ended March 31, 2026, and recommended a final dividend of ₹34 (340%) per equity share. The record date for determining shareholders eligible for the dividend is set as July 24, 2026. The company will hold its 42nd Annual General Meeting (AGM) on August 4, 2026. Additionally, the board approved the appointment of Dr. Mauricio Futran as an Additional Director and an expansion of capacity at Unit 1 with an investment of ₹143.4 crores.

Neuland Laboratories Ltd has announced its 42nd Annual General Meeting (AGM) scheduled for August 4, 2026. The Board approved audited financial results for the year ended March 31, 2026, and recommended a final dividend of ₹34 (340%) per equity share. Dr. Mauricio Futran was appointed as an Additional Director (Non-Executive Non-Independent), subject to shareholder approval. The company also approved a capacity enhancement at Unit 1 with an investment of ₹143.4 crores.

Neuland Laboratories Ltd has appointed Dr. Mauricio Futran as an Additional Director, categorized as Non-Executive Non-Independent, effective May 12, 2026. This appointment is based on the recommendation of the Nomination and Remuneration Committee and is subject to shareholder approval at the upcoming AGM. The board also approved the audited financial results for the year ended March 31, 2026, recommended a final dividend of ₹34 per share, approved convening the AGM on August 4, 2026, and approved capacity enhancement at Unit 1.

Neuland Laboratories Ltd's board approved audited financial results for the year ended March 31, 2026, recommending a final dividend of ₹34 per equity share. They also appointed Dr. Mauricio Futran as an Additional Non-Executive Non-Independent Director, subject to shareholder approval. The 42nd AGM will be held on August 4, 2026, with a record date of July 24, 2026, for dividend eligibility. Additionally, the company approved a capacity enhancement at Unit 1 with an investment of ₹143.4 crores.

Neuland Laboratories Ltd (NLL) announced its financial results for the quarter and year ended March 31, 2026. Total income for Q4FY26 stood at ₹788.7 crore, a 134.9% increase YoY, and EBITDA was ₹319.4 crore, up by 448.6% YoY. The company reported a profit after tax of ₹212.5 crore, a 666.3% increase compared to Q4FY25. An error in the earnings call link was corrected and a new link provided. The company's CEO, Saharsh Davuluri, expressed satisfaction with the FY26 performance and highlighted investments in peptide manufacturing and a new R&D center.

Neuland Laboratories Ltd's board has recommended a final dividend of ₹34 (340%) per equity share with a face value of ₹10 each for the financial year 2025-26. The dividend will be paid on or after five days from the date of declaration at the 42nd Annual General Meeting (AGM). The company also approved the audited financial results for the year ended March 31, 2026, and appointed Dr. Mauricio Futran as an Additional Director. Additionally, the company approved capacity enhancement at Unit 1 with an investment of ₹143.4 crores.

Neuland Laboratories Limited announced robust financial results for Q4 FY26 and the full year ended March 31, 2026. For Q4 FY26, Total Income surged 134.9% year-on-year to 788.7 crore, while EBITDA soared 448.6% to 319.4 crore, with the EBITDA margin expanding to 40.5%. Profit After Tax (PAT) dramatically increased by 666.3% year-on-year to 212.5 crore. For the full year FY26, the company reported a Total Income of 2053.1 crore and an EBITDA of 603.4 crore. CEO Mr. Saharsh Davuluri highlighted strong business visibility for the short to medium term, driven by commercial and near-commercial molecules, and confirmed ongoing investments in Peptide Manufacturing and a new R&D Centre for future growth. An earnings call is scheduled for May 12, 2026.